

THE

CANCER LETTER

P.O. Box 2370

Reston, Virginia 22090

Telephone 703-620-4646

Vol. 8 No. 37

Sept. 24, 1982

©Copyright 1982
The Cancer Letter Inc.
Subscription \$125 year North
America/\$150 yr elsewhere

NCI EXPECTS 200 CCOP APPLICATIONS; GRAND RAPIDS WORKSHOP TO OFFER LAST CHANCE TO ASK QUESTIONS

NCI now expects to receive 200 applications for the Community Clinical Oncology Program, a figure based on the number and content of letters of intent from organizations responding to the CCOP request for applications.

A total of 232 letters of intent was reviewed by CCOP Program Director Robert Frelick, who said that only about a dozen were from
(Continued to page 2)

In Brief

CANCER ACT RENEWAL NEARS, APPROPRIATIONS BILLS LAG; INTERIM FUNDING LIKELY FOR '83 FISCAL YEAR

CONGRESSIONAL ACTION on health research authorization, including renewal of the National Cancer Act, is imminent, with the House scheduled to take up the bill this week. When the Senate bill reaches the floor, it will face a variety of amendments, including the one mandating continuation of NCI's Organ Site Program. It is possible Congress will send the measure to the White House before adjournment next month. Not so likely is completion of HHS appropriations legislation. NCI and the rest of the department probably will have to operate under interim funding (a "continuing resolution") for the first few months of the fiscal year, which starts Oct. 1. . . . **NORTHERN CALIFORNIA** Cancer Program joined UCLA and USC in the Cancer Control Research Unit grant application originally developed by the latter two (*The Cancer Letter*, Sept. 3). Donald Austin is coprincipal investigator for NCCP, along with Lester Breslow of UCLA and Brian Henderson of USC. Austin is associate director of NCCP and chief of the California Tumor Registry. . . . **BRIAN HENDERSON**, chairman of the Dept. of Community and Family Medicine at the Univ. of Southern California, will be the interim director of the USC Comprehensive Cancer Center when Richard O'Brien leaves next month to become dean of the Creighton Univ. School of Medicine. A search committee is in the process of looking for a permanent director. . . . **TOXICOLOGY LABORATORY** design and management for the '80s and beyond is the theme of a national conference sponsored by the National Assn. of Life Science Industries. The conference will be held Sept. 26-29 at the Hyatt Regency Crystal City in Arlington, Va. Contact NALSI Executive Director Howard Brown, 1919 Pennsylvania Ave. N.W., Suite 702, Washington D.C. 20006, phone 202-466-4464. . . . **MICHAEL KLEIN**, acting chief of NCI's Program Analysis & Formulation Branch, has retired. He worked in the Office of Program Planning & Analysis since 1967. . . . **JAMES BOWEN**, associate vice president for research at the Univ. of Texas System Cancer Center, has been named vice president for academic affairs.

1986 International Cancer Congress

To Be In Budapest

. . . Page 2

Program Announcements, RFA In Radiation

Effects Available

. . . Page 5

NCI Advisory Group, Other Cancer Meetings

. . . Page 3

RFPs Available

. . . Page 6

Contract Awards

. . . Page 8

NO CCOP PREPROPOSAL MEETING PLANNED, ADMINISTRATOR'S CONFERENCE SCHEDULED

(Continued from page 1)

organizations clearly not qualified or eligible. A few were advised to abandon their independent efforts and to associate with others.

Frelick wrote responses to each letter. "We tried to be constructive, and told some where they were weak. Many were not as well prepared as they might have been."

Those deemed eligible received along with Frelick's letter a formatted application consisting of 10-12 tables to be filled out. Use of a standardized application had been opposed by some of those who participated in drawing up the CCOP guidelines, but Frelick said most of the opponents now agreed that it would be helpful. "It spells out the information we want, in a form that will be easier to analyze," he said. Responders are not limited to the form and are asked to supply narrative explanations where appropriate.

NCI is not planning an overall preproposal conference, as had been suggested earlier. A conference for administrators is tentatively scheduled for Oct. 13 at NIH (Bldg. 1, Wilson Hall, 10 a.m.). Anyone may attend, but the program will be limited to aspects of grants management.

The symposium on "Cancer Care in the Community Hospital," sponsored by the Grand Rapids Clinical Oncology Program Sept. 29-Oct. 1 offers CCOP applicants one last opportunity to have their questions answered by NCI executives. Peter Greenwald, director of the Div. of Resources, Centers & Community Activities; Jerome Yates, director of DRCCA's Centers & Community Oncology Program; and Frelick will be on hand for a four hour CCOP workshop Oct. 1. The conference will be held at the Amway Grand Plaza Hotel. For information and registration, contact Diane VanOstenberg, Grand Rapids Clinical Oncology Program, 100 Michigan N.E., Grand Rapids, Mich. 49503, phone 6160774-1230.

Now that he has completed the response to the letters of intent, Frelick said he hopes to spend some time analyzing them to a greater degree. "I was impressed by the extent of community hospital involvement in supportive care," he said. The letters indicated hospitals are deeply involved in up to date home care, family support, chapel services, and a variety of other cancer control type activities.

"Our cancer control efforts may have paid off more than we have realized," Frelick said. "There are marked changes in the number of oncology nurses, oncology units, tumor boards, tumor registries, team care. Things are happening. There must be a fantastic amount of hospice type activity going on."

Frelick also was impressed by the number of "reasonably experienced" clinical investigators in-

involved in the CCOP letters of intent. "Some are quite experienced, former principal investigators at major institutions and now in private practice."

The letters of intent indicate that a large majority of CCOPs will be consortia of hospitals and/or clinics, and some of them will be very large. An example is the effort being put together in Oregon, in which nearly all the hospitals in the state will be involved.

"That will make the review complicated, and it will be difficult to deal fairly with the large and small groups," Frelick said. The review is being organized and will require three ad hoc review committees.

Applications are due Nov. 9. The review schedule will be established so that the entire process, including site visits, will be completed in time for presentation to the National Cancer Advisory Board at its meeting scheduled for May 16-18, 1983. First awards probably will go out by July 1, 1983.

NCI has made available \$10 million to fund the program with FY 1983 money.

NEXT INTERNATIONAL CANCER CONGRESS WILL BE HELD IN BUDAPEST IN 1986

The 14th International Cancer Congress will be held in Budapest during late August-early September 1986. The Council of the International Union Against Cancer (UICC), which sponsors the Congress, selected Budapest during the 13th Congress last week in Seattle.

President of the 1986 Congress will be Professor Lapis, who heads pathology at the Univ. of Budapest. Secretary General will be Prof. Eckhart, director of the Budapest Cancer Institute.

New members elected to the UICC Council are S. Barg, Argentina; W. Bodmer, United Kingdom; J. Holzner, Austria; B.G. Lissaios, Greece; E. Mirand, U.S.; N. Napalkov, U.S.S.R.; I. de Nunes, Panama; T. Morali, Tunisia; R.H. Dent, United Kingdom; J.H.C. Ho, Hong Kong; Claude Lagarde, France; J. Ostina, Colombia; P.A. Voute, Netherlands; D. Hossfeld, West Germany.

Mirand and R. Flamant, France, were elected to the Executive Committee. A.C.C.C. Junqueira of Brazil in the current UICC president and Gerald Murphy, U.S., is secretary general.

Awards for outstanding contributions to UICC and the fight against cancer were presented to Lane Adams, executive vice president of the American Cancer Society; O. Jacobsson, executive secretary of the Norwegian Cancer Society; Audrey Mars, U.S.; N. Blokhin, U.S.S.R. and a past president of UICC; and E. Caseres, director of the National Cancer Institute of Peru.

Two new UICC divisions were established—Detection and Diagnosis, chaired by Umberto Veronesi, UICC immediate past president; and Treatment and Rehabilitation, chaired by I. Elsebai, Cairo.

**NCI ADVISORY GROUP, OTHER CANCER
MEETINGS FOR OCT., NOV., FUTURE**

Frontiers in Medicine: Implications for the Future—Oct. 1-2, Beverly Hills, Calif. Contact Health Sciences, UCLA Extension, P.O. Box 24901, Los Angeles 90024, phone 213-825-8421.

Biometry & Epidemiology Contract Review Committee—Oct. 1, NIH Bldg. 31 Rm 8, open 9-9:30 a.m.

Swiss Cancer Congress—Oct. 1-2, St. Gail. Therapeutic modalities in potentially curable malignant tumors. Contact P. Siegenthaler, Swiss Cancer League, Monbijourstr 61, Postfach 2284, 3001 Bern, Switzerland.

National Cancer Advisory Board Subcommittee on Organ Site Programs—Oct. 3, NIH Bldg 31 Rm 6, 7:30 p.m., open.

National Cancer Advisory Board—Oct. 4-6, NIH Bldg 31 Rm 6, 8:30 a.m. each day, closed all day Oct. 5.

NCAB Subcommittee on Planning & Budget—Oct. 4, NIH Bldg 31 Rm 10A52, 7:30 p.m., open.

Interscience Conference on Antimicrobial Agents & Chemotherapy—Oct. 4-6, Miami Beach. Contact R.R. Clark, ASM, 1913 L St. NW, Washington D.C. 20006.

7th European Symposium on Hormones & Cell Regulation—Oct. 4-7, Sainte-Odile, France. Contact Dr. R. Denton, Dept. of Biochemistry, Univ. of Bristol Medical School, Bristol BS8 1TD, Great Britain.

Cancer Screening and Detection Seminar—Oct. 4, Houston. Contact Judy Patterson, M.D. Anderson Hospital, 6723 Bertner Ave., Rm HMB-3.201, Houston 77030.

International Cancer Symposium—Oct. 4-6, Chicago. Contact Dr. Ray Crispin, ITR Biomedical Research, Univ. of Illinois, 904 W. Adams St., Chicago 60607.

Cellular Systems for Toxicity Testing—Oct. 5-7, New York. Contact Conference Dept., New York Academy of Sciences, 2 E. 63rd St., New York 10021, phone 212-838-0230.

NCAB Subcommittee on Review of Budget & Contracts of the Office of Director—Oct. 6, NIH Bldg 31 Rm 4, 12:30 p.m.

NCI Div. of Resources, Centers & Community Activities Board of Scientific Counselors—Oct. 7-8, NIH Bldg 31 Rm 6, 8:30 a.m.

Advances in Pediatric Oncology, Care of the Child & Family—Oct. 7-8, New York City. Contact N. Houlihan, RN, APON Program, 511 E. 80th St., New York 10021.

Cancer in the Elderly: An Interdisciplinary Perspective—Oct. 7-8, Roswell Park continuing education in oncology. Contact Gayle Bersani, RPMI, 666 Elm St., Buffalo N.Y. 14263.

Genetics in Clinical Oncology—Oct. 7-8, New York, Contact Dr. R.S.K. Chaganti, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York 10021.

Current Concepts in Psychosocial Oncology—Oct. 7-9, New York. Contact Charlene Landis, CME Conference Planners, Memorial Sloan-Kettering, address above.

New York State Cancer Programs Annual Meeting—Oct. 8-9, Roswell Park Memorial Institute, Buffalo. Contact Dr. Edwin Mirand, RPMI, 666 Elm St., Buffalo 14263.

Cancer and the Environment—Oct. 8, Health Education Bldg., Medical College of Ohio, Toledo. Contact Northwest Ohio Cancer Network, phone 419-381-3717.

5th South African International Radiological Congress—Oct. 8-15, Johannesburg, Republic of South Africa. Contact P. Reichmann, POB 2251, Johannesburg, 200.

9th UICC Training Course in Cancer Research—Oct. 10-21, Rehovot, Israel. Contact Prof. Gideon Berke, Dept. of Cell Biology, Weitzmann Institute, Rehovot 76100.

12th Symposium on Neuroradiologicum—Oct. 10-16, Bethesda. Contact Dr. G. diChiro, Neuroradiology Computed Tomography Section, Clinical Center, Bldg. 10 Rm 11N240, Bethesda, Md. 20205, phone 301-496-6801.

NCI Div. of Cancer Treatment Board of Scientific Counselors—Oct. 11-12, NIH Bldg 31 Rm 10, 8:30 a.m. both days, closed Oct. 11, 5-7 p.m.

Sixth Annual Cancer Symposium—Oct. 11-13, Vacation Village Hotel, San Diego. Sponsored by Scripps Memorial Hospital. Contact Nomi Feldman, 3770 Tansy, San Diego 92121, phone 714-453-6222.

Cancer Symposium for Nurses—Oct. 11-13, Islandia Hyatt House, San Diego. Contact Nomi Feldman, address above.

4th World Congress on Diseases of the Chest—Oct. 11-13, Toronto. Contact A. Soffer, American College of Chest Surgeons, 911 Busse Highway, Park Ridge, Ill. 60068.

Southeastern Cancer Research Assn.—Oct. 14-15, Quality Inn, Gatlinburg, Tenn. Contact Dr. Wayne Criss, Cancer Center, Howard Univ., Washington D.C. 20060.

Symposium on Dentistry and Cancer—Oct. 14, Roswell Park continuing education in oncology.

Piedmont Oncology Assn. Third Annual Conference—Oct. 15-16, Inn on the Plaza, Asheville, N.C. Contact POA, Bowman Gray School of Medicine, Oncology Research Center, 300 S. Hawthorne Rd., Winston-Salem, N.C. 27103, phone 919-748-4464.

10th World Congress of Gynecology & Obstetrics—Oct. 17-22, San Francisco. Contact American College of Ob/Gyn, POB 23578, Washington D.C. 20024.

Breast Cancer—An Update—Oct. 17-22, Las Vegas, Nev. Contact Dr. Erwin Witkin, Society for Continuing Medical Education, Suite 208, Baltimore, Md. 21215, phone 301-358-1541.

Chromosomes and Cancer: From Molecules to Man—Oct. 18-19, Univ. of Chicago. Fifth annual Bristol-Myers symposium on cancer research. Contact Dr. Janet Rowley or Dr. John Ulmann, Univ. of Chicago Cancer Research Center, Box 444, 950 E. 59th St., Chicago 60637.

Cancer Control Grant Review Committee—Oct. 18-19, NIH Bldg 31 Rm 8, open Oct. 18, 8:30-9 a.m.

Cancers Induced by Therapeutic Modalities—Oct. 18, Paris. Contact Mrs. Berthomeau, Institut Curie, 26 rue d'Ulm, 75231, Paris, Cedex 05, France.

German and Swiss Radiation Protection Union—Oct. 18-22, Munich. Contact Gesellschaft fur Strahlen und Umweltforschung GmbH, Ingolstradter Landstr. 1, 8042, Neuherberg, Fed. Rep. of Germany.

7th International Symposium of the World Assn. of Veterinary Microbiologists, Immunologists, and Specialists in Infectious Diseases—Oct. 18-21, Barcelona. Contact Dr. Juan Plana Duran, Gran Via de les Cortes Catalanes, 794 bajos (Chaflan Lepanto), Barcelona 13, Spain.

NCI Div. of Cancer Biology & Diagnosis Board of Scientific Counselors—Oct. 20-22, NIH Bldg 31 Rm 10 first day, Rm 8 following days; 9 a.m.

9th Annual Symposium on Dermatopathology: Pitfalls in Diagnosis of Malignant Melanoma—Oct. 21-23, New York. Contact Dr. Bernard Ackerman, Dermatopathology Section, NYU Medical Center, 530 First Ave., New York 10016, phone 212-340-7250.

Computers in Medical Practice—Oct. 21, Roswell Park continuing education in oncology.

Nutrition and Cancer—Oct. 22-23, Chapel Hill, N.C. Contact Dr. William Heizer, Cancer Research Center, Box 30, MacNider Bldg., Univ. of North Carolina, Chapel Hill 27514.

William B. Castle Symposium on Advances in Hematology—Oct. 22, Boston. Contact Dr. Andrew Schafer, Hematology Div., Brigham & Women's Hospital, 75 Francis St., Boston 02115, phone 617-732-5844.

New England Chapter Society of Nuclear Medicine—Oct. 22-24, Newport, R.I. Contact Education Resources Associates, P.O. Box 369, Brookline, Mass. 02146, phone 617-738-8859.

10th International Tutorial on Clinical Cytology—Oct. 23-30, Vienna. Contact C.M. Weil Center for Continuing Education, Univ. of Chicago, 1307 E. 60th St., Chicago, Ill. 60637.

Interscience Conference on Antimicrobial Agents & Chemotherapy—Oct. 24-26, Las Vegas, Nev. Contact R.R. Clark, ASM, 1913 L St. NW, Washington D.C. 20006.

American Society of Therapeutic Radiologists—Oct. 25-29, Orlando Hyatt House. Contact S.A. Aubin, 20 N. Wacker Dr., Rm 2920, Chicago, Ill. 60606.

1st World Congress on Trophoblast Neoplasms—Oct. 25-27, Lagos, Nigeria. Contact Medical College of Wisconsin, Dept. of Ob/Gyn, 8700 W. Wisconsin Ave., Milwaukee 53226.

Cancer Nursing: Today and Tomorrow—Nov. 1-2, Johns Hopkins Medical Institutions, Baltimore. Contact Program Coordinator, Turner 22, 720 Rutland Ave., Baltimore, Md. 21205, phone 301-955-6046.

Cancer Clinical Investigation Review Committee—Nov. 1-2, NIH Bldg 31 Rm 6. Open Nov. 1, 8:30-9 a.m.

Annual Course in Pediatric Radiology—Nov. 1-3, Cambridge, Mass. Contact Educational Resources Associates, P.O. Box 369, Brookline, Mass. 02146, phone 617-738-8859.

3rd Annual International Congress for Interferon Research—Nov. 1-3, Miami. Contact E.R. Ruffing, Scherago Associates, 1515 Broadway, New York 10036, phone 212-730-1050.

International Symposium on Gynecologic Oncology—Nov. 1-9, Amsterdam. Contact Erwin Witkin, SCME, 6609 Reisters-town Rd., Baltimore Md. 21215, phone 301-358-1541.

Current Controversies in Breast Cancer—Nov. 3-5, Shamrock Hilton Hotel, Houston. Contact Cochairmen Drs. George Blumenschein, Eleanor Montague, or Frederick Ames, M.D. Anderson Hospital, 6723 Bertner Ave., Houston, Tex. 77030.

Double Contrast Techniques in Gastrointestinal Radiology—Nov. 3-6, Vienna. Contact Prof. Dr. H. Pokieser, Secretariat, Zentrales Institut für Radiodiagnostik der Universität Wien, Allgemeines Krankenhaus, A-1090 Wien, Alserstrasse 4, Austria.

Lung Cancer: Diagnosis & Therapy—Nov. 4, Roswell Park continuing education in oncology. Contact Gayle Bersani, Cancer Control Coordinator.

American Pancreatic Assn. and National Pancreatic Cancer Project—Nov. 4-5, Chicago. Contact Dr. Isidore Cohn, NPCP, Louisiana State Univ. Medical Center, 1542 Tulane Ave., New Orleans 70112.

International Symposium on Radioimmunoimaging: A State of the Science Update—Nov. 4-5, Albuquerque. Contact Dr. Buck Rhodes, Nuc-Med Inc., P.O. Box 13329, Albuquerque, N.M. 87192, phone 505-294-5197.

5th Annual San Antonio Breast Cancer Symposium—Nov. 5-6, San Antonio, Texas. Contact Terri McDaniel, Cancer Therapy & Research Center, 4450 Medical Dr., San Antonio 78229, phone 512-690-0655.

Cincinnati Conference on Cancer Therapy: Breast Cancer—Nov. 5-6. Contact Thomas O'Connor, Cancer Treatment Center, Bethesda Hospital, 619 Oak St., Cincinnati, Ohio 45206, phone 513-559-6337.

EORTC Symposium on Paraneoplasia Basic Concepts and Clinical Aspects—Nov. 5-6, Brussels. Contact Dr. M. Staquet, EORTC Data Center, rue Heger-Bordet 1, 1000 Brussels, Belgium.

5th Annual Meeting and Symposium of the National Hospice Organization—Nov. 7-10, Washington D.C. Contact 1982 Fall Meeting, P.O. Box 207, Davidsonville, Md. 21035.

President's Cancer Panel—Nov. 8, NIH Bldg 31 Rm 4, 9 a.m., open.

30th Annual Scientific Meeting of the American Society of Cytology—Nov. 8-13, Chicago. Contact Dr. Warren Lang, Secretary-Treasurer, 130 S. 9th St., Suite 810, Philadelphia, Pa. 19107.

Innovative Cancer Chemotherapy Tomorrow—Nov. 10-12, New York. Chemotherapy Foundation Symposium. Contact

Director, Page & Wm. Black Post Graduate School of Medicine, Mount Sinai School of Medicine, SUNY, Annenberg 5-206, 1 Gustave Levy Pl., New York 10029, phone 212-650-6772.

Inorganic and Nutritional Aspects of Cancer and Other Diseases—Nov. 10-13, La Jolla. Third conference of the International Assn. of Bioinorganic Scientists. Contact Dr. G.N. Schrauzer, Chemistry Dept., Univ. of California (San Diego), Revelle College, La Jolla 92093.

Cancer Special Programs Advisory Committee—Nov. 15-16, Linden Hill Hotel, Bethesda, Md. Open Nov. 15, 9-10 a.m.

Applications of Biological Markers to Carcinogen Testing—Nov. 15-19, Bethesda, Md. Symposium sponsored by the Environmental Protection Agency. Contact Claire Wilson, Associate Universities Inc., Suite 603, 1717 Massachusetts Ave. N.W., Washington D.C. 20036, phone 202-462-4475.

National Surgical Adjuvant Project for Breast & Bowel Cancers—Nov. 15-17, San Antonio. Contact Dr. Bernard Fisher, Univ. of Pittsburgh School of Medicine, 3550 Terrace St., Pittsburgh, Pa. 15261, phone 412-624-2671.

Tutorial on Neoplastic Hematopathology—Nov. 15-19, Chicago. Contact Claude Weil, Univ. of Chicago, Center for Continuing Education, 1307 E. 60th St., Chicago 60637, phone 312-753-3186.

Controversies in the Management of Early Breast Cancer—Nov. 17, Biltmore Hotel, Los Angeles. Contact Bonnie Van-Waardenburg, Hospital of the Good Samaritan, 616 S. Witmer St., Los Angeles, Calif. 90017, phone 213-977-2345.

Contemporary Issues in Osteoporosis—Nov. 18, Roswell Park continuing education in oncology.

Cancer Centers Support Grant Review Committee—Nov. 18, NIH Bldg 31 Rm 10, open 8:30-10 a.m.

Annual Scientific Meeting on Clinical Oncology—Nov. 24-26, Sydney, Australia. Contact Clinical Oncological Society of Australia, Box 4708 GPO, Sydney NSW, Australia.

Radiological Society of North America—Nov. 28-Dec. 1, McCormack Place, Chicago. Contact American College of Radiology, 20 N. Wacker Dr., Chicago, Ill. 60606, phone 312-236-4963.

National Cancer Advisory Board—Nov. 29-Dec. 1, NIH Bldg 31 Rm 6, 8:30 a.m., open all three days for annual program review.

FUTURE MEETINGS

New Concepts in the Management of Head and Neck Cancer—Dec. 9, Chicago. Interdisciplinary efforts in the diagnosis, management and rehabilitation of head and neck cancer patients, societal factors which may influence patient management. For surgeons, dentists, oncologists, nurses. Contact Margaret Stewart, Administrative Coordinator, Illinois Comprehensive Cancer Center, 36 S. Wabash Ave., Chicago 60603, phone 312-346-9813.

Clinical Cytopathology for Pathologists—April 18-29, 1983, Johns Hopkins Univ. School of Medicine and Johns Hopkins Hospital, Baltimore, Md. Applications are due before Feb. 2, 1983, and the home study course starts in February. Designed for pathologists who are certified or qualified by the American Board of Pathology or the international equivalents. A refresher course in all aspects of clinical cytopathology. Contact Dr. John Frost, 610 Pathology Bldg., Johns Hopkins Hospital, Baltimore 21205.

Fourth International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy—June 22-24, Shelburne, Vt. Convened by the Norris Cotton Cancer Center and the Vermont Regional Cancer Center. New developments in the biology, chemistry, pharmacodynamics, toxicology, and clinical aspects of platinum and other metal complexes as they relate to cancer therapy. Poster abstracts are due by Dec. 31. Contact Joan MacKenzie, VRCC, 1 S. Prospect St., Burlington, Vt. 05401, phone 802-656-4414.

PROGRAM ANNOUNCEMENT

Title: *Oncogene products in irradiated cells and tissues*

NCI's Div. of Cancer Treatment desires to expand its support of radiation effects research. The program is seeking applications for research grants concerned with testing the hypothesis that oncogene expression occurs as a step in radiation induction of some tumors. Experiments are to be designed to detect the presence of oncogene products in irradiated cells or tissues that convert to malignant behavior in vitro and/or in vivo.

Methods to be used may include, but need not be limited to, the use of immunocytochemical markers or cDNA probes. Although it is expected that emphasis will be placed on experiments that seek retrovirus gene products, tumor antigens thought to be produced by certain DNA viruses may also be sought. Any biological test system may be used for study, but the ultimate goals of the program would benefit greatly from the study of human cells.

In making this program announcement, it is not the intent of the National Cancer Institute to make or imply any delimitation of research related to oncogene expression, but rather to stimulate investigator-initiated research in this particular field.

Applications in response to this announcement will be reviewed on a nationwide basis in competition with each other, and in accord with the usual NIH peer review procedures. Applications will be accepted in accordance with the usual NIH receipt dates for new applications: March 1, July 1, and Nov. 1.

Applications should be submitted on form PHS-398, which is available in the grants and contracts business office at most academic and research institutions or from the Div. of Research Grants, NIH. The title of this program announcement should be typed in section 2 on the front page of the grant application form.

In addition, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement. The original and six copies of the application should be sent or delivered to: Applications Receipt Office, Div. of Research Grants, NIH, Westwood Bldg. Rm. 240, Bethesda, Md. 20205.

For further information, investigators are encouraged to contact: Dr. James L. Murray, Low-Level Radiation Effects Branch, Div. of Cancer Treatment, NCI, Bldg. 31 Rm. 4B29, Bethesda, Md. 20205, phone 301-496-9326.

In order to alert DCT to the submission of proposals with primary thrust directed to radiation effects research, a copy of the covering letter should be sent to Murray.

PROGRAM ANNOUNCEMENT

Title: *Specific radiation-induced chromosomal abnormalities and cancer*

NCI's Div. of Cancer Treatment is seeking applications for research grants for basic studies to answer questions concerning the relationship between radiation induced chromosomal translocations and radiation induced cancer.

For example, are specific translocations found in recently transformed irradiated cells; do radiation induced animal tumors consistently contain cells that are nearly euploid but contain specific translocations; and can evidence be found for chromosomal abnormalities as an etiologic factor in human radiogenic tumors? In making this program announcement, it is not the intent of NCI to make or imply any delimitation of research related to chromosomal abnormalities, but rather to stimulate investigator initiated research in this particular field.

Studies to be proposed should consider promising areas of research using cytogenetic methods in experiments involving in vitro cell transformation, animal tumor induction, or putative radiogenic cancers in human patients. Experimental plans should clearly identify the biological system(s) to be used, criteria for malignancy to be applied, and cytogenetic procedures to be utilized. Because one of the most likely cytogenetic endpoints to be assayed is the unbalanced translocation, it is expected that chromosome banding procedures, with quantitative measurements, if necessary, will be used in the cytogenetic aspects of the study. The use of a particular biological system should be justified on the basis of its potential for simultaneous cytogenetic study in carcinogenesis experiments.

Applications will be accepted in accordance with the usual NIH receipt dates for new applications: March 1, July 1, and Nov. 1.

Applications should be submitted on form PHS 398. In addition, a brief covering letter should accompany the application indicating it is being submitted in response to this program announcement. The original and six copies of the application should be sent or delivered to the NIH Applications Receipt Office. (see previous announcement for address).

For further information, investigators are encouraged to contact Dr. James L. Murray at the same address in the previous announcement. A copy of the covering letter should be sent to Dr. Murray.

RFA NIH-NCI-DCT-LLREB-82-15

Title: *Carcinogenesis in small animals irradiated in utero*

Application Receipt Date: Dec. 1, 1982

The Div. of Cancer Treatment of NCI invites grant applications from interested investigators for basic studies to measure the carcinogenic effects of low

levels of ionizing radiation on the developing embryo and fetus in small animals.

This type of grant solicitation (the RFA) is utilized when it is desired to encourage investigator initiated research projects in areas of special importance to the National Cancer Program. Applicants funded under the RFA are supported through the customary NIH grant in aid. However, the RFA solicitation represents a single competition, with a specified deadline for receipt of applications. All applications received in response to the RFA will be reviewed by the same NIH initial review group.

The Low Level Radiation Effects Branch of the Radiation Research Program, NCI, has as its major interest the effects of low levels of ionizing radiation on biological systems. For the purposes of the LLREB, low level is defined as acute exposures less than 10 rad. The major radiation effects occurring at these doses are mutagenesis, carcinogenesis, and in utero effects. LLREB has specific interests in each of these low level effects including the influence of dose rate and LET.

Each year thousands of women are given radio-diagnostic examinations of the abdomen during pregnancy. The effects of these small doses of radiation on the developing embryo/fetus are a matter of controversy. Several human studies suggest that doses of 1-2 rad may increase the postnatal cancer risk; however, other epidemiologic studies have not confirmed this. Factors such as gestational age at time of exposure and maternal health status are likewise not well understood. Clearly, the risks of radiation exposure during pregnancy must be more clearly defined in order to facilitate benefit/risk decision making in clinical practice.

This RFA is responsive to the Congressional mandate under the Biological Research Extension Act of 1978 (PL 95-622) as well as to the recommendations of the Interagency Radiation Research Committee's Federal Strategy for Research into the Biological Effects of Ionizing Radiation (June, 1981).

The carcinogenic effects of low levels of ionizing radiation on the developing embryo and fetus in small animals are to be measured in order to define the risks of radiation exposure during development. Any small laboratory animal system may be used. Single cell, tissue and organ systems may also be used where appropriate, such as in investigations of mechanisms of radiation effects in utero. Proposed studies should evaluate cancer induction in small animals following a wide range of radiation doses, including low doses. Factors influencing cancer induction such as gestational age at exposure, maternal health and endocrine status should also be considered in the study design. Other factors which may be studied include dose rate and LET. Analysis of the data may include dose response curves at low doses and comparison of the types of tumors produced.

Responsibility for the planning, direction, and execution of the proposed research will be solely that of the applicant. The total project period for applications submitted in response to the present RFA should not exceed five years. The intent is to fund several projects, with total program costs amounting to approximately \$400,000 for the first year. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. Also, although this program is provided for in the financial plans of the NCI, the award for grants pursuant to this RFA is contingent upon the availability of funds for this purpose.

Applications must be submitted on form PHS 398 (Revised 5/80), the application form for research project grants. The conventional presentation in format and detail applicable to regular research grant applications should be followed. The number and title of this RFA should be typed in section 2 on the front page of the grant application form.

The completed original and six copies should be sent or delivered to: Div. of Research Grants, NIH, Westwood Bldg. Rm 240, Bethesda, Md. 20205.

One copy of this application should also be sent to each of the following individuals: Dr. Harold Waters, Div. of Research Grants, NIH, Westwood Bldg. Rm. 2A16, Bethesda, Md. 20205, and to Dr. James L. Murray, Low Level Radiation Effects Branch, Div. of Cancer Treatment, NCI, Bldg 31 Rm. 4B29, Bethesda, Md. 20205, telephone 301-496-9326. Inquiries may be directed to Dr. Murray.

RFPs AVAILABLE

Requests for proposal described here pertain to contracts planned for award by the National Cancer Institute unless otherwise noted. Write to the Contracting Officer or Contract Specialist for copies of the RFP, citing the RFP number. NCI listings will show the phone number of the Contracting Officer or Contract Specialist who will respond to questions. Address requests for NCI RFPs to the individual named, the Blair Building room number shown, National Cancer Institute, 8300 Colesville Rd., Silver Spring, Md. 20910. RFP announcements from other agencies reported here will include the complete mailing address at the end of each.

RFP NCI-CM-37559

Title: *Master agreements for computer programming support task orders*

Deadline: *Approximately Oct. 29*

NCI's Div. of Cancer Treatment, Developmental Therapeutics Program, Information Technology Branch, is seeking organizations to provide system design, development, and programming services. These services will be used under quick reaction task order contracts. This is a 100 percent small business set aside.

It is anticipated that, under these agreements, a number of tasks will be undertaken, as the need for

them arises. However, at this time, no specific details can be provided for any particular task. In general, programs will be required for maintenance support, operations support, or development support. Objectives may be the conversion of a file from one graphic format to another, the substitution of parallel telecommunication by a multiplexer, and the interfacing of a software package or new equipment with an existing system. The resolution of specific operating problems may also be involved.

Experience is required in planning and designing scientific information systems, with information management and principles, in implementing large and complex scientific data bases; in the use of graphics, with graphic terminals such as the Hewlett-Packard 2647A and 2648A, with SERSATEC printer/plotters and their software packages; in data communication, in particular with selection of multipoint networks, data concentrators, and various types of multiplexers; in the selection, use and interfacing with mainframe, micro- and minicomputers; in planning, implementing and monitoring security procedures for online multiterminal systems; in system performance and productivity optimization.

Each contractor must name a program director and a task order project leader. A chemist/biologist and a mathematician should be part of the staff.

Quick reaction agreements are master contracts which are competitively negotiated and awarded to more than one contractor. Task orders are then awarded to master agreement awardees, after competitive bids have been solicited from a suitable qualified subgroup of the master contractors. This type of contract is designed to accomplish specified pieces of work promptly.

It is anticipated that several awards will be made as the result of this RFP. It is also anticipated that each award will be for three years. Initial awards will be unfunded. Only task orders awarded under the master agreements will be funded. It is estimated that three task orders will be awarded per year.

Contract Specialist: Charles Lerner
RCB, Blair Bldg. Rm. 228
301-427-8737

RFP NCI-CM-27553-19

Title: *Clinical trials monitoring service*

Deadline: *Nov. 24*

The Cancer Therapy Evaluation Program, Div. of Cancer Treatment, NCI, is requesting organizations which possess research and development capabilities to submit proposals for conducting a clinical trials monitoring service.

This service involves two distinct areas: (1) data capture, managing and procuring of patient data; (2) clinical trials monitoring of investigational drug studies for data quality assurance and compliance to

FDA and HHS regulations.

Data Capture Management and Processing. The data base and management system will contain patient information on approximately 2,500 patients entered on phase 1 and selected phase 2 investigational drug trials per year. Interested parties must demonstrate the following minimum capabilities, specifically: a. Ability to continue current data base using contractor provided: (1) Ramsis II or equivalent data base management software; (2) all hardware required to implement the data management system. Familiarity of clinical data involving new investigational drug trials (phase 1 & 2).

Clinical Trials Monitoring Site Visits. Interested parties must demonstrate the capability of performing the following: a. phase 1 and selected phase 2 trials: 30 site visits by physicians, 60 site visits by clinical research associates. b. Cooperative group co-site visits and single and multi-institution site visits: 100 site visits by clinical research associates.

Personnel. Interested parties demonstrate the availability of the following key personnel: a. Personnel with expertise in computerized data management and clinical trials data system. b. An experienced physician with working knowledge of site visit monitoring of investigational anticancer drug studies. c. Clinical Research Associates who are experienced in all aspects of site visit monitoring. d. Personnel with in-depth knowledge of FDA and HHS regulations in regards to investigational drug clinical trials. Information furnished should include the total number of employees and professionals, qualifications of scientists and technical personnel; a description of general and special facilities and outline of previous projects; a statement regarding industrial security clearance, if previously granted; and other descriptive literature.

The anticipated level of effort is approximately 23,177 person-hours per year based on 2,080 hours. One award will be made.

Contract Specialist: Kristina Mott
RCB, Blair Bldg. Rm. 228
301-437-8737

RFP NCI-CM-37565-27

Title: *Dose calculations for treatment with radioactively labeled antitumor antibodies*

Deadline: *Dec. 1*

Develop methods for standardizing the calculation of radiation doses to tumors and normal tissues with the various isotopes (alpha, beta or gamma emitters) likely to be used in cancer patient therapy. Calculational methods must be correlated with three-dimensional anatomy (as defined by CT scanning, ultrasound, NMR, single photon emission computed tomography (SPECT), or positron emission tomography (PET) and should be compatible with conventional

radiotherapy treatment planning systems insofar as possible.

Participating institutions will participate in a collaborative effort to develop consensus criteria and guidelines for dose calculations with radioactively labeled antitumor antibodies. Each contractor shall enter a minimum of 30 patients yearly for a four year period. Each contractor must have the ability to synthesize radioactively labeled compounds and document access to sources of alpha, beta and gamma emitters, especially those with short radioactive half-lives. Possession of or documented access to a positron emission tomographics (PET) scanner and/or a single photon emission computer tomographic (SPECT) scanner for use with phantoms and patients is required.

RFP NCI-CM-37564-27

Title: *Comparative clinical NMR imaging studies*

Deadline: *Dec. 1*

Develop criteria and guidelines for the use of NMR imaging systems for clinical applications in the detection, imaging, quantification, and diagnosis of morphological and functional pathology in human subjects and in the noninvasive characterization of tissues.

Collaborate with other participating institutions in a working group to develop common criteria and guidelines for the performance of diagnostic and evaluative studies. Formulate plans and protocols for specific comparative studies employing NMR imaging systems with other selected imaging modalities.

Perform, evaluate and report the comparative results of such studies in applications of imaging for various diseases and in various parts of the body as determined by proposals from the offerors and recommendations from NCI.

Each contractor shall enter a minimum of 150 patients in year one and 200 patients each for years two and three of a three year period. Each contractor must have the availability of or access (1) to NMR imaging equipment and (2) to imaging equipment of other modalities needed for making the required clinical comparisons. In addition, comparative clinical evaluation studies using NMR whole body or head imaging systems and other appropriate diagnostic imaging modalities for diseases are to be proposed by the offeror.

Contracting Officer for the

above two RFPs: Roland Castle
RCB, Blair Bldg. Rm 219
301-427-8737

RFP NCI-CM-37567

Title: *Primary and detailed in vivo screening for anticancer activity*

Deadline: *Approximately Nov. 15*

NCI's Div. of Cancer Treatment, Developmental Therapeutics Program, Drug Evaluation Branch, is seeking organizations possessing facilities for housing sufficient numbers of rodents (primarily mice, both conventional and conventional plus athymic) and possessing the capability to maintain and transplant tumor lines, to prepare materials for testing, to conduct a minimum of 20,000 test equivalents per year, and to report all test data for computer processing on forms and format furnished by NCI.

A test equivalent is based on the work effort required to carry out an IP L1210 assay, with IP treatment for nine consecutive days using six mice per test group plus appropriate controls. Organizations must have the capability to conduct testing in a number of in vivo tumor assays, primarily the P388 tumor test system and other systems such as L1210, B16 melanoma, M5076, etc., MB mammary xenograft, etc.

Offerors must possess the capability and resources for in vivo screening at a minimum level of 20,000 test equivalents per year. The principal investigator must have experience in the in vivo testing of drugs in rodents. Proposals will be invited for a five year contract period at the following levels: 20,000; 30,000 and 40,000 test equivalents per year. Proposals may be submitted for testing in conventional only or both conventional and athymic test models.

It is anticipated that multiple awards will be made as a result of this RFP. It is also anticipated that each award will be for a five year incrementally funded period of performance. Awards will be made at the test equivalent levels most advantageous to the government.

Contract Specialist: Charles Lerner
RCB, Blair Bldg. Rm. 228
301-427-8737

NCI CONTRACT AWARDS

Title: Serum collection from volunteer participants in the Breast Cancer Detection Demonstration projects, continuation

Contractor: Cancer Research Center, Columbia, Mo. \$24,270.

Title: Screening technique for blood in the stool as a means of detecting early cancer of the bowel, continuation

Contractor: Univ. of Minnesota, \$1,063,600.

The Cancer Letter

Editor Jerry D. Boyd

Published forty-eight times a year by The Cancer Letter, Inc., P.O. Box 2370, Reston Virginia 22090. Also publisher of The Clinical Cancer Letter. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.